Diagnostics company bioMerieux (PARIS:BIM) has received 510(k) clearance from the U.S. Food and Drug Administration for a test to detect and screen for methicillin-resistant staphylococcus, more ...

bioMérieux, French manufacturer of diagnostic solutions, has received FDA 510(k) approval for NucliSENS EasyQ MRSA, an automated molecular test for MRSA, according to a company news release. The test ...

The Food and Drug Administration (FDA) has authorized marketing of a new diagnostic test, cobas vivoDx MRSA (Roche Molecular Systems Inc), to detect methicillin-resistant Staphylococcus aureus (MRSA) ...

Company Offers Most Comprehensive, Cost-Effective Suite of Solutions to Detect and Screen for Methicillin Resistant Staphylococcus aureus (MRSA) “bioMérieux is committed to bringing innovative ...

The Illinois Department of Public Health announced the publication of the first infection surveillance data on Clostridium difficile and methicillin-resistant Staphylococcus aureus rates from lab ...

The CDC estimates around 5% of U.S. hospital patients carry MRSA infections on their skin or in in their nose. In many cases, these carriers will never develop harmful infections with MRSA. However, ...

Easy-to-use molecular test offers faster results to help healthcare facilities control spread of methicillin-resistant Staphylococcus aureus (MRSA) "It is important that healthcare professionals have ...

October 26, 2008 (Washington, DC) — Diagnostic technology that uses bacteriophages has the potential to quickly identify pathogens and their drug sensitivity to better guide therapy. Initial data on ...

The US Food and Drug Administration (FDA) has approved a new, faster diagnostic test based on bacterial viability and a novel technology to detect methicillin-resistant Staphylococcus aureus (MRSA) ...

For the first time, Illinois hospitals have released data on the rates of Clostridium difficile and methicillin-resistant Staphylococcus aureus from lab results. This data is available on the Illinois ...